Drug intelligence / Profile preview

SBX 2048

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBX 2048 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of HIV infection and associated immunodeficiency. The therapeutic is derived from a proprietary database of over 8,000 medicinal plants and is designed to control viral replication while simultaneously improving the patient's immune response. In June 2022, Stramsen Biotech announced SBX 2048 as one of eleven candidates selected for clinical development. The drug represents part of the company's broader strategy to leverage natural products for complex infectious and immunological conditions.

Beyond the preview

Go deeper on SBX 2048.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX 2048.

Explore the full profile